Evgen Pharma PLC Update on extended-use phase of STEM trial (1803N)
September 23 2019 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 1803N
Evgen Pharma PLC
23 September 2019
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Update on extended-use phase of STEM clinical trial
Evgen Pharma (AIM: EVG) a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces that five patients who participated in the
STEM trial ("STEM") received SFX-01 treatment for over one year,
with two of these five patients continuing to be treated with
SFX-01. For these five patients, SFX-01 halted their previously
progressive tumour growth for the full six month period of the
trial and for at least a further six months of extended use on
compassionate grounds. Of the two patients continuing to be treated
with SFX-01, one has now reached 438 days of dosing, and the other,
476 days; the latter exceeding the previous best of 448 days.
All patients entering STEM had ER+ metastatic (Stage 4) breast
cancer and had confirmed progressive disease at the point of entry
into the study (i.e. their tumour(s) had grown more than 20% since
their last scan) and thus become resistant to their current and all
prior treatments. SFX-01 was then administered in addition to the
current failing therapy to investigate whether it was possible, in
this advanced stage of disease, to elicit a clinical benefit by
halting growth or shrinking the tumours(s).
As announced on 25 March 2019, the trial met both primary
endpoints with approximately 25% of patients demonstrating clinical
benefit for the full six month duration of the trial. Patients that
continued to have a benefit at six months were able to continue on
SFX-01 in an extension phase.
The news of this sustained response to SFX-01, comes just days
before the Company is due to present the STEM results via a
scientific poster at ESMO (European Society for Medical Oncology)
in Barcelona on 29 September. A link to the poster will be
announced shortly after its presentation.
Steve Franklin, CEO of Evgen Pharma, commented: "We are
delighted that these patients continue to benefit from SFX-01 after
their participation in the STEM trial. This patient group has
failed on all previous therapies and have very few options
remaining. We could not have expected to see this kind of enduring
benefit in such late stage disease and so we continue to plan with
heightened confidence the on-going development of SFX-01 in ER+
metastatic breast cancer - targeting the earlier stages of the
disease before resistance to all endocrine therapies is
established. In this earlier part of the treatment path, one would
expect SFX-01 to have even more impact where its role will be to
significantly extend the utility of endocrine therapies without
increasing the side effect burden."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
----------------------------------
Dr Stephen Franklin, CEO
----------------------------------
Richard Moulson, CFO
----------------------------------
finnCap www.finncap.com +44 (0) 20 7220 0500
----------------------------------
Geoff Nash / Teddy Whiley (Corporate
Finance)
------------------------------------------
Alice Lane, Manasa Patil (ECM)
----------------------------------
WG Partners LLP +44 (0) 20 3705 9330
----------------------------------
Nigel Barnes / Claes Spång
----------------------------------
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
----------------------------------
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
----------------------------------
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
The Company commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESPGUMUBUPBGAU
(END) Dow Jones Newswires
September 23, 2019 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024